HealthTech and MedTech companies operate at the intersection of healthcare, regulation, and technology. Digital health platforms deliver telemedicine, patient engagement, and clinical workflow software. MedTech companies build medical devices and diagnostic hardware with FDA pathways. Digital therapeutics products combine clinical validation with reimbursement-based revenue. Healthcare data platforms operate adjacent to EHR systems, payer data, and clinical research. Across the category, finance complexity comes from regulatory pathways, reimbursement-based revenue, multi-payer collection mechanics, HIPAA infrastructure costs, value-based and outcomes contracts, MedTech inventory and consignment accounting, and the grant funding common at pre-revenue stages. The model differs from typical SaaS economics in regulatory timeline, payment structure, compliance overhead, and the long product cycles that healthcare innovation requires. This page covers what makes HealthTech and MedTech accounting distinct, and the services available to address it.

Executive Summary

• FDA approval pathways and regulatory milestones drive financial planning, with capitalization decisions on clinical and regulatory costs requiring explicit policy and audit-grade documentation.
• Reimbursement-based revenue creates collection lag, denial rates, and revenue cycle accounting mechanics that don’t apply to typical software businesses.
• Multi-payer payment mix (commercial insurance, Medicare, Medicaid, employer, patient self-pay) introduces different timing, collection rates, and accounting requirements per payer category.
• HIPAA compliance, protected health information infrastructure, and healthcare-specific cybersecurity requirements drive cost categories that don’t exist in non-health tech.
• Grant and non-dilutive funding from NIH, BARDA, SBIR, and state programs is common at pre-revenue stages and requires specific accounting under ASU 2018-08 and related guidance.

What HealthTech and MedTech Companies Look Like as a Business

The HealthTech and MedTech category covers several distinct business types:

• Digital health platforms delivering telemedicine, virtual care, patient engagement, or clinical workflow software
• MedTech and medical device companies building hardware with FDA 510(k), De Novo, or PMA pathways and ongoing service or consumables revenue
• Digital therapeutics (PDT) companies offering clinically validated software treatments with FDA clearance and reimbursement-based revenue
• Healthcare data and analytics platforms operating around EHR systems, claims data, or clinical research workflows
• Diagnostic and lab platforms delivering testing services with reimbursement and CLIA compliance requirements
• Pharma tech and clinical trial platforms serving life sciences with R&D infrastructure, study management, or regulatory submission tools
• Population health and value-based care platforms serving payers, providers, and risk-bearing entities
• Healthcare AI applications applying AI and ML to clinical workflows, diagnostics, or care management (with overlap to AI startup economics)

What distinguishes HealthTech and MedTech from other technology categories is the combination of regulatory framework, payment structure, and compliance overhead. Most HealthTech companies operate under HIPAA. MedTech and digital therapeutics companies typically navigate FDA pathways with multi-year regulatory timelines. Reimbursement-based business models bring insurance billing, denial management, and net revenue calculations that resemble healthcare provider accounting more than software accounting. Long pre-revenue cycles common in MedTech and digital therapeutics create capital strategy challenges around grant funding, milestone-based equity raises, and the burn rate required to sustain regulatory work through commercialization.

What Makes HealthTech and MedTech Accounting Distinct

FDA pathways and regulatory cost capitalization

MedTech and digital therapeutics companies typically navigate FDA approval pathways (510(k), De Novo, or PMA) with multi-year regulatory timelines and substantial cost. Capitalization decisions on clinical study costs, regulatory submission costs, and pre-approval activities are genuinely complex. Some costs may qualify for capitalization as part of the device or product asset; others must be expensed as research costs. The accounting captures regulatory cost categories explicitly, with policy documentation supporting the chosen treatment. Negative regulatory outcomes (FDA rejection, required additional studies) can trigger impairment of capitalized costs, with material write-downs possible. The chosen accounting policy needs ongoing reassessment as the regulatory pathway progresses.

Reimbursement-based revenue and revenue cycle accounting

HealthTech companies billing insurance, Medicare, Medicaid, or employer-sponsored plans face revenue cycle mechanics distinct from typical SaaS billing. The accounting captures gross charges, contractual allowances (the difference between billed and contracted rates), denials, appeals, and ultimate collection. Net revenue is recognized after estimating collection probability, with reserve methodology supporting the estimate. Collection lag from claim submission to payment can run thirty to ninety days or longer, affecting both revenue timing and cash flow forecasting. Denials and appeals create operational workload and revenue volatility. Revenue cycle management infrastructure (often outsourced to specialized vendors) flows through cost of revenue. The accounting and operational discipline resembles healthcare provider revenue cycle work more than software business mechanics.

Multi-payer payment mix and accounting

Different payers have different mechanics. Commercial insurance pays at contracted rates with formal denial and appeals processes. Medicare and Medicaid pay at government-set rates with their own coding, billing, and audit requirements. Employer-sponsored direct contracts typically have shorter payment cycles. Patient self-pay involves patient responsibility (deductibles, copays, coinsurance) and collection mechanics resembling consumer billing. Out-of-pocket cash-pay business sometimes runs alongside insurance billing as a separate revenue line. The accounting captures revenue by payer category, with collection rates, denial patterns, and payment timing tracked separately for each. Payer mix affects gross margin, working capital, and the financial planning required to support operations.

Value-based and outcomes-based contracts

Value-based care contracts pay based on outcomes, quality metrics, capitation arrangements, or shared savings rather than fee-for-service. Examples include shared-savings arrangements with payers (the platform shares in cost reductions), capitation contracts (per-member-per-month payments), bundled payments (single payment covering multiple services), and outcomes-based pricing (payment tied to clinical results). The accounting treatment under ASC 606 requires variable consideration analysis, constraint estimation (the amount that should be deferred until outcomes resolve), and ongoing reassessment as actual outcomes emerge. Long measurement periods (some shared-savings arrangements measure annual cost reductions) create revenue recognition timing challenges. Outcomes accounting is one of the more technically complex revenue recognition areas in HealthTech.

HIPAA compliance and PHI infrastructure costs

Companies handling protected health information (PHI) operate under HIPAA’s Privacy Rule, Security Rule, and Breach Notification Rule. HIPAA-compliant infrastructure (HIPAA-eligible cloud services, dedicated environments, encryption, access controls), business associate agreements with vendors, ongoing security audits, and breach response capabilities all create cost categories that don’t exist in non-health tech. The accounting captures HIPAA infrastructure cost as a recurring operating expense category. Annual HIPAA security risk assessments, penetration testing, and ongoing compliance monitoring add operational overhead. Vendor risk management for any third party touching PHI adds procurement and contracting overhead. SOC 2 Type II reporting (often expected by enterprise health customers) layers on top of HIPAA requirements.

Grant accounting and non-dilutive funding

HealthTech and MedTech startups commonly receive substantial grant funding from NIH, BARDA, NSF, SBIR/STTR, state programs, and disease-specific foundations. Grant accounting under ASU 2018-08 (Not-for-Profit Entities and Conditions on Contributions) determines whether grants are conditional or unconditional, exchange transactions or contributions, and how revenue or contra-expense recognition should occur. Conditional grants recognize as conditions are met (often as qualifying expenses are incurred). The accounting captures grant revenue or expense offset, restricted versus unrestricted balances, and compliance with grant-specific spending requirements. Improper grant accounting creates audit findings and can affect future grant eligibility. Grant-funded operations may also require time-and-effort reporting for personnel charged to grants.

Clinical trial costs and CRO management

MedTech, digital therapeutics, and pharma tech companies running clinical trials face clinical trial cost accounting that combines fixed costs (study setup, regulatory submission, IRB) and variable costs (per-patient enrollment, site fees, per-procedure payments). Most studies use Contract Research Organizations (CROs) under multi-million dollar contracts with milestone-based payment structures. The accounting captures CRO obligations, milestone progress, and the relationship between study completion and cost recognition. Multi-year studies with site-by-site enrollment ramp create cost timing decisions. Study modifications, protocol amendments, and changing enrollment timelines all affect financial reporting. Reserve adequacy for future study obligations becomes a significant balance sheet item for clinically active companies.

MedTech inventory and consignment accounting

Medical device companies often place inventory on consignment at hospital sites: the device sits at the hospital, but title and ownership remain with the MedTech company until use. Consignment inventory accounting requires explicit tracking of units placed at each site, units used, and the timing of revenue recognition (typically at use, not at shipment). Cycle counts at consignment sites become an operational requirement. Manufacturing cost flows through standard inventory accounting (raw materials, work in process, finished goods) with cost-of-goods-sold recognition tied to revenue events. Loaner devices, demonstration units, and capital equipment that customers don’t purchase outright create their own asset and depreciation accounting. Warranty obligations, service contracts, and consumables revenue add post-sale revenue streams that need explicit tracking.

Telemedicine and state licensing economics

Telemedicine platforms face state-by-state medical licensing requirements affecting which clinicians can deliver care to patients in each state. Multi-state operations require networks of licensed clinicians, friendly-PC corporate structures (where required by corporate practice of medicine doctrine), and state-specific compliance. The accounting captures clinician network costs, state licensing infrastructure, and the operational cost of multi-state delivery. Friendly-PC structures (where the platform contracts with a physician-owned professional corporation that holds the medical practice) create unique multi-entity accounting patterns. State medical board audits, ongoing licensing compliance, and the legal infrastructure required to operate cross-state add overhead specific to telemedicine.

Long pre-revenue cycles and capital strategy

MedTech and digital therapeutics companies often spend years pre-revenue working through regulatory pathways, clinical validation, and commercial readiness before generating meaningful revenue. Capital strategy has to sustain operations through long product cycles, with funding rounds typically structured around regulatory milestones (IND filing, study enrollment, pivotal trial readout, FDA approval, commercial launch) rather than typical software metrics. Investor expectations differ: revenue and growth metrics aren’t yet meaningful, so milestone-based valuation methodology and clinical or regulatory progress drive valuation conversations. Burn rate, runway extension to next milestone, and the relationship between capital raised and milestones achieved become central planning topics. Bridge financing and venture debt sometimes fill gaps between equity rounds tied to specific milestones.

Services for HealthTech and MedTech Companies

Fractional CFO leadership

Senior finance leadership for HealthTech and MedTech operations. Multi-year financial planning aligned with regulatory and clinical milestones, capital strategy across long pre-revenue cycles, grant management, reimbursement strategy, payer mix optimization, fundraising support, board reporting tied to clinical and regulatory progress, M&A diligence response, and the institutional readiness work that scaled health companies need. For our general fractional CFO services, see the fractional CFO services page.

Accounting and bookkeeping

Day-to-day accounting work for HealthTech and MedTech operations. Reimbursement-based revenue recognition with denial and collection reserves, multi-payer revenue tracking, value-based contract accounting under ASC 606, regulatory cost capitalization or expense treatment, grant accounting under ASU 2018-08, clinical trial cost accruals, MedTech inventory and consignment tracking, HIPAA compliance cost reporting, and consolidated financial reporting that supports both internal management and audit requirements. See startup accounting services for broader scope.

Consulting and advisory

Project-based engagements for specific HealthTech and MedTech challenges. Regulatory cost capitalization policy design. Reimbursement revenue methodology and denial reserve framework. Value-based contract revenue analysis under ASC 606. Grant accounting framework. Clinical trial cost accrual methodology. Consignment inventory framework. Internal controls design for HIPAA-regulated operations. SOC 2 Type II readiness preparation. SOX compliance readiness for companies approaching public-company status. Audit readiness for HealthTech companies preparing for first audit, IPO, or M&A diligence. See accounting consulting services for additional detail.

Frequently Asked Questions

How are FDA regulatory and clinical costs accounted for?

Capitalization decisions on clinical study costs, regulatory submission costs, and pre-approval activities are genuinely complex. Some costs may qualify for capitalization as part of the device or product asset; others must be expensed as research costs. The accounting captures regulatory cost categories explicitly, with policy documentation supporting the chosen treatment. Negative regulatory outcomes (FDA rejection, required additional studies) can trigger impairment of capitalized costs. The chosen accounting policy needs ongoing reassessment as the regulatory pathway progresses.

How is reimbursement-based revenue recognized?

The accounting captures gross charges, contractual allowances (the difference between billed and contracted rates), denials, appeals, and ultimate collection. Net revenue is recognized after estimating collection probability, with reserve methodology supporting the estimate. Collection lag from claim submission to payment can run thirty to ninety days or longer. Different payer categories (commercial insurance, Medicare, Medicaid, employer, self-pay) have different mechanics tracked separately for each.

How are value-based and outcomes-based contracts accounted for?

Value-based contracts pay based on outcomes, quality metrics, capitation, or shared savings rather than fee-for-service. The treatment under ASC 606 requires variable consideration analysis, constraint estimation (the amount that should be deferred until outcomes resolve), and ongoing reassessment as actual outcomes emerge. Long measurement periods create revenue recognition timing challenges. Outcomes accounting is one of the more technically complex revenue recognition areas in HealthTech.

How is grant funding accounted for?

Through ASU 2018-08 analysis determining whether grants are conditional or unconditional, exchange transactions or contributions, and how revenue or contra-expense recognition should occur. Conditional grants recognize as conditions are met (often as qualifying expenses are incurred). The accounting captures grant revenue or expense offset, restricted versus unrestricted balances, and compliance with grant-specific spending requirements. Grant-funded operations may also require time-and-effort reporting for personnel charged to grants.

How are HIPAA compliance costs reflected in financial reporting?

HIPAA-compliant infrastructure (HIPAA-eligible cloud services, dedicated environments, encryption, access controls), business associate agreements, ongoing security audits, and breach response capabilities all create cost categories. The accounting captures HIPAA infrastructure cost as a recurring operating expense category. Annual HIPAA security risk assessments, penetration testing, ongoing compliance monitoring, and SOC 2 Type II reporting expected by enterprise health customers add operational overhead.

How is MedTech consignment inventory accounted for?

Consignment inventory at hospital sites requires tracking of units placed at each site, units used, and the timing of revenue recognition (typically at use, not at shipment). Title and ownership remain with the MedTech company until the device is used. Cycle counts at consignment sites become an operational requirement. Manufacturing cost flows through standard inventory accounting with cost-of-goods-sold recognition tied to revenue events. Loaner devices, demonstration units, and capital equipment create their own asset and depreciation accounting.

What’s distinct about clinical trial cost accounting?

Clinical trial cost accounting combines fixed costs (study setup, regulatory submission, IRB) and variable costs (per-patient enrollment, site fees, per-procedure payments). Most studies use Contract Research Organizations (CROs) under multi-million dollar contracts with milestone-based payment structures. The accounting captures CRO obligations, milestone progress, and the relationship between study completion and cost recognition. Reserve adequacy for future study obligations becomes a significant balance sheet item for clinically active companies.

Reviewed by YR, CPA
Senior Financial Advisor